MATERIAL SAFETY DATA SHEET

Product Name: Procainamide Hydrochloride Injection

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address
Hospira Inc.
275 North Field Drive
Lake Forest, Illinois USA
60045

Emergency Telephone
CHEMTREC: North America: 800-424-9300;
International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418

Hospira, Inc., Non-Emergency
224-212-2000

Product Name
Procainamide Hydrochloride Injection

Synonyms
ρ-amino-N-[2-(diethylamino) ethyl] benzamide mono-hydrochloride

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name
Procainamide Hydrochloride

Chemical Formula
C_{13}H_{21}N_{3}O \cdot HCl

Preparation
Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% may include methylparaben and sodium metabisulfite. Sodium hydroxide and/or hydrochloric acid may be use to adjust the pH.

<table>
<thead>
<tr>
<th>Component</th>
<th>Approximate Percent by Weight</th>
<th>CAS Number</th>
<th>RTECS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide Hydrochloride</td>
<td>≤50</td>
<td>614-39-1</td>
<td>CV2295000</td>
</tr>
</tbody>
</table>

3. HAZARD INFORMATION

Carcinogen List

<table>
<thead>
<tr>
<th>Substance</th>
<th>IARC</th>
<th>NTP</th>
<th>OSHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide Hydrochloride</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

Emergency Overview
Procainamide Hydrochloride Injection is a solution containing procainamide hydrochloride, an anti-arrhythmic agent used in the treatment of both atrial and ventricular arrhythmias. In the workplace, this product should be considered potentially irritating to the eyes and respiratory tract. This product also contains a sulfite and may cause an allergic reaction in persons sensitive to sulfites. Based on clinical use, possible target organs include the heart, hematopoietic system, immune system and possibly the skin.

Occupational Exposure Potential
Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms
None known from occupational exposure. In clinical use, adverse effects may include gastrointestinal effects such as anorexia, bitter taste, abdominal pain, nausea, vomiting and diarrhea. Effects on the nervous system may include dizziness, giddiness, seizure, mental depression, confusion, and psychosis with hallucinations. Dermatologic effects may include
Product Name: Procainamide Hydrochloride Injection

urticaria, pruritis, and a maculopapular rash. Procainamide hydrochloride is also cardiotoxic. Toxicities may include an increase in ventricular rate when used for atrial fibrillation or flutter; tachycardia; widening of the QRS (and other conduction delays); and an increased risk of complete heart block, especially with a history of 1st or 2nd degree heart block. Elevations in liver function tests [AST (SGOT), ALT (SGPT)] and amylase may occur rarely. Persons who are sensitized to procaine or other ester-type anesthetics may develop cross-reactivity. Manifestations may be allergic dermatitis, asthma, or anaphylaxis.

Medical Conditions Aggravated by Exposure

Hypersensitivity to the material and/or similar materials; hypersensitivity to sulfites; pre-existing skin, blood, or cardiovascular ailments.

### 4. FIRST AID MEASURES

**Eye contact**
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin contact**
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation**
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion**
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

### 5. FIRE FIGHTING MEASURES

**Flammability**
None anticipated for this aqueous product.

**Fire & Explosion Hazard**
None anticipated for this aqueous product.

**Extinguishing media**
As with any fire, use extinguishing media appropriate for primary cause of fire.

**Special Fire Fighting Procedures**
No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

**Spill Cleanup and Disposal**
Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

### 7. HANDLING AND STORAGE

**Handling**
No special handling required for hazard control under conditions of normal product use.

**Storage**
No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary
Product Name: Procainamide Hydrochloride Injection

container label, or the product insert.

Special Precautions No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Exposure Guidelines</th>
<th>Exposure limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Component</td>
<td>Type</td>
</tr>
<tr>
<td>Procainamide Hydrochloride</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>

Respiratory protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA’s 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin protection

If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye protection

Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls

Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical/Chemical Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance/Physical State</td>
<td>Liquid</td>
</tr>
<tr>
<td>Color</td>
<td>Clear and colorless</td>
</tr>
<tr>
<td>Odor</td>
<td>NA</td>
</tr>
<tr>
<td>Odor Threshold:</td>
<td>NA</td>
</tr>
<tr>
<td>pH:</td>
<td>5.0 (4.0 to 6.0)</td>
</tr>
<tr>
<td>Melting point/Freezing point:</td>
<td>NA</td>
</tr>
<tr>
<td>Initial Boiling Point/Boiling Point Range:</td>
<td>NA</td>
</tr>
<tr>
<td>Evaporation Rate:</td>
<td>NA</td>
</tr>
<tr>
<td>Flammability (solid, gas):</td>
<td>NA</td>
</tr>
<tr>
<td>Upper/Lower Flammability or Explosive Limits:</td>
<td>NA</td>
</tr>
<tr>
<td>Vapor Pressure:</td>
<td>NA</td>
</tr>
<tr>
<td>Vapor Density:</td>
<td>NA</td>
</tr>
<tr>
<td>Specific Gravity:</td>
<td>NA</td>
</tr>
<tr>
<td>Solubility:</td>
<td>NA</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water:</td>
<td>NA</td>
</tr>
<tr>
<td>Auto-ignition temperature:</td>
<td>NA</td>
</tr>
<tr>
<td>Decomposition temperature:</td>
<td>NA</td>
</tr>
</tbody>
</table>
Product Name: Procainamide Hydrochloride Injection

10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Reactivity</th>
<th>Not determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Stability</td>
<td>Stable under standard use and storage conditions.</td>
</tr>
<tr>
<td>Hazardous Reactions</td>
<td>Not determined</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>Not determined</td>
</tr>
<tr>
<td>Incompatibilities</td>
<td>Not determined</td>
</tr>
<tr>
<td>Hazardous decomposition products</td>
<td>Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and hydrogen chloride.</td>
</tr>
<tr>
<td>Hazardous Polymerization</td>
<td>Not anticipated to occur with this product.</td>
</tr>
</tbody>
</table>

11. TOXICOLOGICAL INFORMATION

Acute Toxicity
Not determined for the product formulation. Information for the ingredients is as follows:

<table>
<thead>
<tr>
<th>Ingredient(s)</th>
<th>Percent</th>
<th>Test Type</th>
<th>Route of Administration</th>
<th>Value</th>
<th>Units</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide Hydrochloride</td>
<td>100</td>
<td>LD50</td>
<td>Oral</td>
<td>1509</td>
<td>mg/kg</td>
<td>Rat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>701</td>
<td>mg/kg</td>
<td>Mouse</td>
</tr>
<tr>
<td>Procainamide Hydrochloride</td>
<td>100</td>
<td>LD50</td>
<td>Intravenous</td>
<td>95</td>
<td>mg/kg</td>
<td>Rat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>95</td>
<td>mg/kg</td>
<td>Mouse</td>
</tr>
</tbody>
</table>

Aspiration Hazard
None anticipated from normal handling of this product.

Dermal Irritation/Corrosion
None anticipated from normal handling of this product.

Ocular Irritation/Corrosion
None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing.

Dermal or Respiratory Sensitization
None anticipated from normal handling of this product. However, this product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatics than in non-asthmatic people.

Reproductive Effects
Studies in animals to evaluate the affect on fertility or development have not been conducted.

Mutagenicity
Studies to evaluate the mutagenic potential have not been conducted.

Carcinogenicity
Long-term studies in animals to evaluate the carcinogenic potential have not been conducted.

Target Organ Effects
Based on clinical use, possible target organs include the heart, hematopoietic
Product Name: Procainamide Hydrochloride Injection

system, immune system and possibly the skin

12. ECOLOGICAL INFORMATION

Aquatic Toxicity  Not determined for product
Persistence/Biodegradability  Not determined for product
Bioaccumulation  Not determined for product
Mobility in Soil  Not determined for product

13. DISPOSAL CONSIDERATIONS

Waste Disposal  All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal  Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS:  Not regulated
IMDG STATUS:  Not regulated
ICAO/IATA STATUS:  Not regulated
Transport Comments:  None

15. REGULATORY INFORMATION

USA Regulations

<table>
<thead>
<tr>
<th>Substance</th>
<th>TSCA Status</th>
<th>CERCLA Status</th>
<th>SARA 302 Status</th>
<th>SARA 313 Status</th>
<th>PROP 65 Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide Hydrochloride</td>
<td>Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
</tr>
<tr>
<td>RCRA Status</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. OSHA Classification</td>
<td>Target Organ Toxin</td>
<td>Possible Irritant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GHS Classification</td>
<td>*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hazard Class</td>
<td>Not Applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5
Product Name: Procainamide Hydrochloride Injection

Hazard Category
Not Applicable

Signal Word
Not Applicable

Symbol
Not Applicable

Prevention
P260 - Do not breathe dust/fume/gas/mist/vapors/spray.

Hazard Statement
Not Applicable

Response:
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling.

Get medical attention if you feel unwell.

EU Classification*
*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance Procainamide Hydrochloride.

Classification(s):
Not Applicable

Symbol:
Not Applicable

Indication of Danger:
Not Applicable

Risk Phrases:
Not Applicable

Safety Phrases:
S23 - Do not breathe vapor.
S24 - Avoid contact with skin.
S25 - Avoid contact with eyes.
S37/39 - Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION:

Notes:
ACGIH TLV American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS Chemical Abstracts Service Number
CERCLA US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT US Department of Transportation Regulations
EEL Employee Exposure Limit
IATA International Air Transport Association
LD50 Dosage producing 50% mortality
NA Not applicable/Not available
NE Not established
NIOSH National Institute for Occupational Safety and Health
OSHA PEL US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65 California Proposition 65
RCRA US EPA, Resource Conservation and Recovery Act
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
STEL 15-minute Short Term Exposure Limit
TSCA Toxic Substance Control Act
TWA 8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Product Name: Procainamide Hydrochloride Injection

Date Prepared: 10/19/2012
Obsolet Date: 11/02/2011

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.